Your browser doesn't support javascript.
loading
Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel for moderate-to-severe acne: Efficacy and safety results from two randomized phase 3 trials.
Stein Gold, Linda; Lain, Edward; Del Rosso, James Q; Gold, Michael; Draelos, Zoe D; Eichenfield, Lawrence F; Sadick, Neil; Werschler, William P; Gooderham, Melinda J; Lupo, Mary.
Afiliación
  • Stein Gold L; Henry Ford Hospital, Detroit, Michigan. Electronic address: LSTEIN1@hfhs.org.
  • Lain E; Austin Institute for Clinical Research, Austin, Texas.
  • Del Rosso JQ; JDR Dermatology Research/Thomas Dermatology, Las Vegas, Nevada; Advanced Dermatology and Cosmetic Surgery, Maitland, Florida; Touro University Nevada, Henderson, Nevada.
  • Gold M; Tennessee Clinical Research Center, Nashville, Tennessee.
  • Draelos ZD; Dermatology Consulting Services, PLLC, High Point, North Carolina.
  • Eichenfield LF; Departments of Dermatology and Pediatrics, University of California, San Diego School of Medicine and Rady Children's Hospital, San Diego, California.
  • Sadick N; Department of Dermatology, Weill Cornell Medical College, New York, New York; Sadick Dermatology, New York, New York.
  • Werschler WP; University of Washington, School of Medicine, Seattle, Washington.
  • Gooderham MJ; SKiN Centre for Dermatology, Peterborough, Ontario, Canada.
  • Lupo M; Lupo Center for Aesthetic and General Dermatology, New Orleans, Louisiana.
J Am Acad Dermatol ; 89(5): 927-935, 2023 Nov.
Article en En | MEDLINE | ID: mdl-37656094

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: J Am Acad Dermatol Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: J Am Acad Dermatol Año: 2023 Tipo del documento: Article